Lanean...
CAR T-cell therapy: is it prime time in myeloma?
Chimeric antigen receptor (CAR) T cells have shown promising activity in hematological malignancies and are being studied for the treatment of multiple myeloma, as well. B-cell maturation antigen, which is widely and almost exclusively expressed on plasma cells and B cells, is a promising target. Ot...
Gorde:
| Argitaratua izan da: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Hematology
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913444/ https://ncbi.nlm.nih.gov/pubmed/31808895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000370 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|